Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N‐terminal pro‐brain natriuretic peptide

Objective Our study was to explore the roles between serum soluble suppression of tumorigenicity 2 ( sST 2) and N‐terminal pro‐brain natriuretic peptide ( NT ‐pro BNP ) while evaluating ventricular function to properly diagnose chronic heart failure ( CHF ). Methods In total, 197 CHF patients were recruited and classified into ventricular function's II , III , and IV groups, and 106 healthy people into normal control group. To detect concentrations of Sst2 and NT ‐pro BNP , ELISA and electro‐chemiluminescence immuno assay were implemented. An automatic biochemical analyzer was used to determine the levels of the following: blood urea nitrogen ( BUN ), creatinine (Cr), alanine aminotransferase ( ALT ), triglyceride ( TG ), high‐density lipoprotein cholesterol ( HDL ‐C), low‐density lipoprotein cholesterol ( LDL ‐C), and uric acid ( UA ). A receiver operating characteristic ( ROC ) curve was adopted to detect the diagnostic value sST 2 and NT ‐Pro BNP in CHF and the logistic regression analysis involving the risk factors of CHF . Results Serum sST2 and NT ‐pro BNP concentrations were increased significantly in the ventricular function's II , III , and IV groups in a manner dependent on concentration as opposed to the manner the normal control group occupied. The area under the curve ( AUC ) of sST 2, found NT ‐pro BNP and sST 2+ NT ‐pro BNP to be 0.942 (95% CI : 0.917‐0.966), 0.920 (95% CI : 0.891‐0.948), and 0.968 (95% CI : 0.953‐0.984), respectively. sST 2, NT ‐pro BNP , UA , and Cr were verified as important risk factors of CHF. Conclusion Serum sST 2 and NT ‐Pro BNP could act as diagnostic indicators for CHF .